AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 152 min read$CRSP

KASINGER JAMES R. sold $51K of CRSP

KASINGER JAMES R. (General Counsel and Secretary) sold 1,040 shares of CRISPR Therapeutics AG (CRSP) at $49.26 on 2026-10-14.

Original reporting
SEC EDGAR · KASINGER JAMES R.
Published Oct 15, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 9:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRSP
Bearish
medium confidence
Mentioned
$CRSP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRSPBearishLow
01

Why it matters

This provides incremental sentiment information but does not indicate a new business development, regulatory action, or financial guidance change.

02

Market read

Traders may note the insider sale, but the disclosed transaction size is unlikely to drive material repricing absent other catalysts.

03

What to watch

Insider sales are common and often not predictive; without accompanying operational or guidance changes, the trading signal is weak.

Relevance 3/10Novelty 3/10Timing: filed 2026-10-15, transaction dated 2026-10-14

Background

The article is an SEC Form 4 insider transaction disclosure for CRISPR Therapeutics AG.

Company-level read

Ticker impact

$CRSPBearishMedium confidence
Context

CRSP Form 4 shows General Counsel James R. Kasinger sold 1,040 shares in an open-market transaction for about $51.2K on 2026-10-14.

Expected impact

Likely limited near-term impact, with any reaction confined to sentiment rather than fundamentals.

Evidence & confidence

The filing is a routine insider sale (not a buy, not tied to a new corporate event) and the dollar value is relatively small versus typical CRSP trading/market cap scale.

Market effects

Sector

No clear sector read-through from a single small insider sale.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

The sale may be routine liquidity or tax-related, especially since the filing notes no pre-arranged 10b5-1 plan.

Key entities

  • issuer
    CRISPR Therapeutics AG

    Company whose Form 4 insider sale is disclosed.

  • insider
    KASINGER JAMES R.

    General Counsel and Secretary who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRSP insider trading history →

Related articles

OCT 28
$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.

stocktwits.com2 min
OCT 24
$CRSPMedAI 8/10

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

CRISPR Therapeutics (CRSP) reports promising Phase 1a trial data for CTX310, a gene-editing therapy for high LDL and TG levels, with potential market of 40M+ U.S. patients. The company also shares Casgevy's rights with Vertex (VRTX). CTX310's Phase 1b results are expected in November. CRISPR's pipeline includes other candidates like CTX611, but faces risks of setbacks and market adoption challenges.

finance.yahoo.com3 min